Biomarin Pharmaceutical (BMRN) Share-based Compensation (2009 - 2026)

Biomarin Pharmaceutical has disclosed Share-based Compensation across 18 years of filings, most recently posting $43.5 million for Q1 2026.

• Quarterly Share-based Compensation rose 15.27% year-over-year to $43.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $187.2 million (up 3.39% YoY) and the FY2025 annual result came in at $181.4 million, down 10.0% from the prior year.
• Share-based Compensation retreated to $43.5 million in Q1 2026, from $46.9 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $58.2 million in Q1 2024 and troughed at $37.7 million in Q1 2025.
• A 5-year average of $48.8 million and a median of $47.9 million in 2024 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2023 — Share-based Compensation rose 17.38% — and 2025, when it tumbled 35.28%.
• Tracing BMRN's Share-based Compensation over 5 years: stood at $46.7 million in 2022, then increased by 17.38% to $54.9 million in 2023, then dropped by 5.35% to $51.9 million in 2024, then declined by 9.64% to $46.9 million in 2025, then retreated by 7.36% to $43.5 million in 2026.
• Business Quant data shows BMRN's Share-based Compensation at $43.5 million in Q1 2026, $46.9 million in Q4 2025, and $49.3 million in Q3 2025.